Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

Summary

Participation Requirements

Description

The study will be conducted in approximately 140 sites in about 12 countries. After screening, eligible participants will undergo a 3 to 4-week run-in period to ensure washout of prior medications. At the end of the run-in period, eligible participants will be randomly assigned with a 1:1:1:1:1:1 ra...

The study will be conducted in approximately 140 sites in about 12 countries. After screening, eligible participants will undergo a 3 to 4-week run-in period to ensure washout of prior medications. At the end of the run-in period, eligible participants will be randomly assigned with a 1:1:1:1:1:1 ratio to receive once daily administration of one of the following study treatments group for 12 weeks: AZD9977 Dose A + dapagliflozin 10 mg AZD9977 Dose B + dapagliflozin 10 mg AZD9977 Dose C + dapagliflozin 10 mg AZD9977 Dose C Dapagliflozin 10 mg Placebo Participants will be randomized to one of the above treatment group, according to T2DM (yes/no) and eGFR (<30 mL/min / ? 30 to ? 45 mL/min / >45 mL/min). The total duration of participation will be approximately 19 to 21 weeks.

Tracking Information